Skip to main content
Premium Trial:

Request an Annual Quote

Shimadzu Strikes Mass Spec Software Deals with Phenomenome, Advanced Chemistry Development

NEW YORK, June 21 (GenomeWeb News) - Shimadzu and Phenomenome have inked a deal that will allow researchers to use Phenomenome's informatics platform to visualize and interpret mass spectrometry data generated by Shimadzu technology for metabolomics research, Shimadzu said today.


The collaboration will see data generated on Shimadzu's LC/MS systems integrated with the Phenomenome Profiler informatics platform, Shimadzu said.


In addition, Shimadzu said separately today that it has struck a similar agreement with Advanced Chemistry Development, in which researchers will be able to use ACD software to visualize and interpret mass spectrometry fragmentation data and chromatography data generated by Shimadzu platforms.


Financial terms of the deals were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.